{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:41:04Z","timestamp":1785508864372,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jdiacomp.2023.108411","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:11:44Z","timestamp":1675347104000},"page":"108411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice"],"prefix":"10.1016","volume":"37","author":[{"given":"Nihar R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne B.","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Pantalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108411_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007\u20132012","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0010","author":"IDF"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0015","author":"USRDS"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0025","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0030","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0035","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0045","author":"EMC"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0050","author":"EMA"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0055","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0060","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0080","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0085","author":"FDA"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ejheart.2007.09.008","article-title":"Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey","volume":"9","author":"de Groote","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0095","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0100","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0110","author":"USRDS"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0115","author":"LSE"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0120","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/dom.14915","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.coph.2021.07.010","article-title":"Nonsteroidal mineralcorticoid receptor antagonists: novel therapeutic implication in the management of patients with type 2 diabetes","volume":"60","author":"Greco","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0130","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0135","first-page":"71","article-title":"The role of aldosterone and aldosterone-receptor antagonists in heart failure","volume":"5","author":"Khan","year":"2004","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ph14060561","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"14","author":"Vodo\u0161ek Hojs","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0145","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0150","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0160","first-page":"1","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","author":"Lerma","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14740338.2022.2130889","article-title":"Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective","volume":"21","author":"Marzolla","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2014.01.043","article-title":"Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers","volume":"726","author":"\u0141abuzek","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108411_bb0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:48Z","timestamp":1761005808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1056872723000090"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108411","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108411"}}